Quoin Pharmaceuticals, a Virginia-based specialty pharma company focused on rare and orphan diseases, announced on September 8, 2026 that the FDA has granted Rare Pediatric Disease designation to its lead drug candidate, QRX003, for Peeling Skin Syndrome — a rare inherited disorder that causes the skin’s outer layer to shed excessively, often leaving patients with significant pain and persistent itching, and for which there’s currently no approved treatment. It’s the second time QRX003 has received this designation, following an earlier Rare Pediatric Disease designation the drug earned for Netherton Syndrome.
CEO Michael Myers framed the news as validation that the company’s Phase 2 program, expected to launch in the second half of 2026 and enroll up to a dozen pediatric and adult patients across the U.S. and Europe, is moving forward on schedule.
“We are very pleased to announce the receipt of Rare Pediatric Disease Designation for QRX003 for Peeling Skin Syndrome,” said Dr. Michael Myers, Chief Executive Officer of Quoin Pharmaceuticals. “With the IND cleared by FDA, the Quoin team is preparing to initiate the Phase 2 clinical study before the end of this year with plans to enroll up to 12 pediatric and adult Peeling Skin patients in the U.S. and Europe. This will be the first formal study ever conducted in the U.S. for this disease under an open IND.”
Why the Designation Matters
The FDA’s Rare Pediatric Disease program exists to push drug developers toward diseases that mostly affect children and otherwise attract little commercial investment. The upside for Quoin: if QRX003 eventually wins full approval, the company could become eligible for a Priority Review Voucher — a transferable credit that speeds up review of a future drug application, and one that can also be sold to another company, sometimes for tens of millions of dollars. That potential payoff is part of why designations like this one get attention from investors even well before a drug reaches approval.
A Second Rare Disease, Same Drug
This isn’t Quoin’s first rare-disease milestone for QRX003. The drug previously earned the same FDA designation for Netherton Syndrome, and before that, the European Medicines Agency granted it Orphan Drug status. QRX003 is formulated as a topical lotion that works by blocking kallikrein proteases, targeting what researchers believe is the underlying mechanism behind Netherton Syndrome’s damaged skin barrier. Early clinical results were notable enough to draw coverage from Dermatology Times, which reported that one pediatric patient was able to stop other medications entirely after starting treatment, with no reported adverse effects. Myers has said the company sees comparable underlying biology in Peeling Skin Syndrome, which is part of why it’s pursuing the same drug across both conditions.
Path Forward
Quoin says it plans to begin its Phase 2 study for Peeling Skin Syndrome before year-end. Beyond these two conditions, the company’s pipeline — built around QRX003 and a second platform asset, QRX009 — is aimed at a broader list of rare skin and vascular disorders, including Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome, and several types of vascular malformations.
About Quoin Pharmaceuticals
Quoin Pharmaceuticals is a late-stage clinical specialty pharma company built around two platform technologies, QRX003 and QRX009, both aimed at a wide range of rare and orphan skin and vascular conditions — including the two Peeling Skin Syndrome and Netherton Syndrome programs already in the clinic. The company says its mission is to bring treatment options to patients whose diseases currently have none approved.
